Compare J B Hunt Transport Services Inc (JBHT) vs Sanofi SA (SNY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
J B Hunt Transport Services Inc vs Sanofi SA — how do they compare? J B Hunt Transport Services Inc trades at $265.38 (market cap $24.92B), while Sanofi SA trades at $43.6 (market cap $104.30B). The key difference: Sanofi SA is far larger — about 4.2× J B Hunt Transport Services Inc's market cap, and Sanofi SA pays the higher dividend (5.55%). Which is the better fit depends on your goals.
| JBHT | SNY | |
|---|---|---|
Market Cap | $24.92B | $104.30B |
Sector | Industrials | Health |
52-Week High | $298.41 | $52.34 |
52-Week Low | $130.65 | $41.33 |
Enterprise Value | $26.06B | $124.19B |
Dividend Yield | 0.68% | 5.55% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
JBHT trades at $275.86, up 3.65% today, with a bearish technical signal but strong analyst support. Recent quarters show earnings beats, with Q3 2026 expected at $2.12 EPS. Revenue is projected to grow to $12.7B in 2026, with a net income margin of 5.31%. The company maintains solid profitability metrics, including an 18.45% ROE, and announced a $0.45 dividend payable in August 2026.
The outlook is mixed; strong fundamentals and a $299.82 consensus price target suggest upside, but bearish technicals and competitive pressures pose risks. Investors should weigh earnings consistency against market volatility and sector headwinds for balanced exposure.
SNY trades at $43.62, up 0.32% today, with a neutral technical signal and bullish moving averages. The company reported strong Q2 2026 earnings, beating estimates with EPS of $1.21 versus $1.10 expected, and raised its 2026 outlook. Revenue for 2025 was $46.72B with net income of $7.81B, showing improved profitability. Analyst consensus is mixed with 44% Buy, 52% Hold, and 4% Sell ratings. Recent news highlights regulatory approvals for new drugs and pipeline developments under new CEO leadership.
The outlook for SNY is cautiously optimistic, driven by Dupixent's growth and new drug approvals, but faces risks from pipeline setbacks and competition. Earnings momentum and cost discipline support upside potential, though valuation multiples like a P/E of 23.27 may limit near-term gains. Key risks include biosimilar threats post-2031 and ongoing legal challenges. Institutional activity shows increased holdings, reflecting confidence in the company's strategic direction.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About J B Hunt Transport Services Inc
J.B. Hunt Transport Services ranks among the top surface transportation companies in North America by revenue. Its primary operating segments are intermodal delivery, which uses the Class I rail carriers for the underlying line-haul movement of its owned containers (45% of sales in 2021).
Read more on JBHT →About Sanofi SA
Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 10% of total sales, but profits are shared with Regeneron. About 30% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.
Read more on SNY →
